John Overdeck’s Damora Therapeutics DMRA Stock Holding History

John Overdeck’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Buy	+9,118	New	+$221K	﹤0.01%	4672
2025 Q4	–	Sell	-20,296	Closed	-$75.5K	–	4190
2025 Q3	$75.5K	Buy	+20,296	New	+$68.7K	﹤0.01%	3503
2023 Q3	–	Sell	-509	Closed	-$32.1K	–	3049
2023 Q2	$32.1K	Sell	509 -72	-12%	-$3.92K	﹤0.01%	2873
2023 Q1	$28.9K	Sell	581 -116	-17%	-$6.12K	﹤0.01%	2821
2022 Q4	$20K	Sell	697 -1,165	-63%	-$48.3K	﹤0.01%	2679
2022 Q3	$88K	Sell	1,862 -670	-26%	-$34K	﹤0.01%	2248
2022 Q2	$110K	Sell	2,532 -3,215	-56%	-$147K	﹤0.01%	2259
2022 Q1	$316K	Sell	5,747 -4,526	-44%	-$254K	﹤0.01%	2196
2021 Q4	$778K	Buy	10,273 +4,179	+69%	+$328K	﹤0.01%	2786
2021 Q3	$547K	Buy	+6,094	New	+$652K	﹤0.01%	3171

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

John Overdeck's DMRA Position: Q2 2026 in Review

John Overdeck opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 9,118 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #4672 among its holdings. This is a return to the name: John Overdeck previously reported a position in DMRA as recently as Q3 2025.

John Overdeck first reported a position in DMRA in Q3 2021 and has held it in 10 quarters since. The position peaked at $778K in Q4 2021. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

John Overdeck held 9,118 shares of Damora Therapeutics worth $237K as of Q2 2026.
Damora Therapeutics was a new John Overdeck position in Q2 2026.
Damora Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4672 holding.
John Overdeck first reported a position in Damora Therapeutics in Q3 2021 and has held it in 10 quarters since.
John Overdeck's Damora Therapeutics position peaked at $778K in Q4 2021.
103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.